Abstract
Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.
| Original language | English |
|---|---|
| Pages (from-to) | 921-927 |
| Number of pages | 7 |
| Journal | Human Vaccines & Immunotherapeutics |
| Volume | 13 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 3 Apr 2017 |
Keywords
- adjuvant
- developing countries
- effectiveness
- efficacy
- immunogenicity
- rotavirus
- vaccine
Cite this
}
Options for improving effectiveness of rotavirus vaccines in developing countries. / Tissera, Marion S.; Cowley, Daniel; Bogdanovic-Sakran, Nada; Hutton, Melanie L.; Lyras, Dena; Kirkwood, Carl D.; Buttery, Jim P.
In: Human Vaccines & Immunotherapeutics, Vol. 13, No. 4, 03.04.2017, p. 921-927.Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - Options for improving effectiveness of rotavirus vaccines in developing countries
AU - Tissera, Marion S.
AU - Cowley, Daniel
AU - Bogdanovic-Sakran, Nada
AU - Hutton, Melanie L.
AU - Lyras, Dena
AU - Kirkwood, Carl D.
AU - Buttery, Jim P.
PY - 2017/4/3
Y1 - 2017/4/3
N2 - Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.
AB - Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.
KW - adjuvant
KW - developing countries
KW - effectiveness
KW - efficacy
KW - immunogenicity
KW - rotavirus
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85021308312&partnerID=8YFLogxK
U2 - 10.1080/21645515.2016.1252493
DO - 10.1080/21645515.2016.1252493
M3 - Review Article
VL - 13
SP - 921
EP - 927
JO - Human Vaccines & Immunotherapeutics
JF - Human Vaccines & Immunotherapeutics
SN - 2164-5515
IS - 4
ER -